Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKinsey
Harvard Business School
AstraZeneca
Mallinckrodt

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

GELNIQUE 3% Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Gelnique 3% patents expire, and when can generic versions of Gelnique 3% launch?

Gelnique 3% is a drug marketed by Allergan and is included in one NDA. There is one patent protecting this drug.

This drug has fifty-five patent family members in twenty countries.

The generic ingredient in GELNIQUE 3% is oxybutynin. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxybutynin profile page.

DrugPatentWatch® Generic Entry Outlook for Gelnique 3%

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for GELNIQUE 3%
Recent Clinical Trials for GELNIQUE 3%

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Society for Pediatric DermatologyN/A
University of Colorado, DenverN/A
Astellas Scientific & Medical Affairs, Inc.

See all GELNIQUE 3% clinical trials

US Patents and Regulatory Information for GELNIQUE 3%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 DISCN Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for GELNIQUE 3%

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 ⤷  Try it Free ⤷  Try it Free
Allergan GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 ⤷  Try it Free ⤷  Try it Free
Allergan GELNIQUE 3% oxybutynin GEL, METERED;TRANSDERMAL 202513-001 Dec 7, 2011 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Baxter
Merck
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.